Sentiment Summary
Recent Events
Q2 2026 earnings release is scheduled.
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
Ex-dividend date on 2026-06-29 for the 2025 final dividend of HK$0.0418 per share; Low importance justified by it being a standard technical adjustment scheduled
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
Annual General Meeting on 2026-06-25 to vote on 2025 financial statements and a HK$0.0418 dividend; Low importance justified by the routine nature of the meeting scheduled
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
Ex-dividend date on 2026-06-18 for the FY2025 final dividend of RMB 1.26 per 10 shares, with payment scheduled on or before 2026-07-31; scheduled.
Annual shareholder meeting with an expected ≥1% price impact scheduled
Ex-dividend date on 2026-06-16 for the 2025 final cash dividend of HKD 1.643 per 10 shares, as approved at the AGM on 2026-05-29; payment scheduled for 2026-07-13. Low importance as cash dividends typically have minor price impact.
The 2025 Annual General Meeting to approve the profit distribution plan and annual report on June 12, 2026; market reaction is estimated at Low as it is a routine meeting scheduled.
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
The company granted a total of 14,736,658 restricted share units to four directors, the rotating CEO, certain employees, and a service provider on June 4, 2026.
Entered a commercialization license agreement with Mabworks for exclusive rights to Bejescin® in the Asia-Pacific region on 2026-06-04; medium impact estimated due to strategic regional expansion.
JPMorgan maintained its "Neutral" rating on Ganfeng Lithium but raised its 2026-2028 earnings forecasts by 15-22%, citing higher long-term lithium price assumptions. This update is estimated to have a low price impact of 1-5% as the rating remains neutral despite the forecast raise, and is forecasted.
Announced board approval for FX hedging up to USD 150 million; routine risk management is estimated to have a >1% price impact.
Announced an increase in the guarantee limit for subsidiaries by RMB 300 million; operational support is estimated to have a >1% price impact.
Announced repurchase of 812,400 H-shares for approximately HK$101 million on June 4, 2026, as part of an ongoing share buyback program; low importance as the buyback is routine and likely to result in >=1% price impact.
Announced the initiation of a clinical trial for Dotinurad tablets for gout patients on 2026-06-04; the clinical progress is estimated to have a ≥1% price impact.
Final cash dividend for 2025 of HKD 0.13786 per share approved at the AGM on 2026-06-04, with payment scheduled by 2026-08-04; low importance as standard dividend approvals typically impact price by 1-5% scheduled.
Announced the establishment of a Strategic Development Committee on 2026-06-04 to enhance oversight of major investments and long-term planning; low importance as internal governance changes typically have minimal price impact of 1-5% scheduled.
Shareholders approved a new equity incentive plan and an increase to the employee stock purchase plan at the 2026 Annual Meeting on June 4, 2026, authorizing up to 8.66 million and 4 million new shares, respectively, which could lead to future shareholder dilution.
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
The New Drug Application (NDA) for Olipudase (奥莱泊肽), a GLP-1/GIP dual receptor agonist, was accepted for review by China's NMPA on June 3, 2026. Analysts estimate a >10% price impact due to the drug's significant market potential expected.
Major shareholder CBC Group purchased 690,000 shares for approximately HKD 20 million on 2026-06-03; medium impact estimated due to significant insider buying signaling confidence.
Appointed oncology leaders Dr. Thomas Lynch and Dr. Eric Rubin to the company's board of directors.
Held its 2026 Annual General Meeting where all proposals, including director elections and an equity plan amendment, were approved. Estimated 1% price impact as routine governance matters were confirmed.
Management participated in the Jefferies 2026 Global Healthcare Conference on June 3, 2026.
Associate company Legend Biotech announced on June 2, 2026, positive preliminary clinical data for its in vivo CAR-T cell therapy, LB2501, for non-Hodgkin lymphoma, leading to a significant stock price increase.
Announced an exclusive licensing agreement to out-license civorebrutinib to Travere Therapeutics for $112.5M upfront and up to $1.03B in milestones on 2026-06-02; high impact estimated due to the substantial deal value.
On June 2, 2026, the company announced updated data for mesutoclax in MDS and AML at ASCO 2026 showing high efficacy; high impact due to clinical success expected.
Personalis announced positive clinical data from the ASCO 2026 meeting (May 29-June 2), showing its NeXT Personal MRD test had 100% sensitivity for colorectal cancer relapse and strong performance across six solid tumor types.
Following the AGM on 2026-06-02, Dr. Ye Xiaoping was re-elected as Chairman and Mr. Wen Zengyu was appointed as General Manager; low impact expected from routine leadership continuity.
Announced on June 2, 2026, the appointment of Raj Jampa as the new Chief Technology Officer, effective June 1, 2026.
Company executives presented at the William Blair 46th Annual Growth Stock Conference on 2026-06-02, reiterating the company's strategy and financial outlook, including the target for adjusted EBITDA breakeven in Q4 2026.
Announcement of the U.S. commercial launch of the Prosigna Breast Risk of Recurrence test on June 8, 2026, following positive Phase III OPTIMA trial data expected; high importance estimated due to potential for significant market expansion.
Presentation of positive results from the Phase III OPTIMA and ENZAMET clinical trials at the ASCO 2026 meeting expected; high importance estimated due to clinical data supporting key diagnostic products.
Announced on 2026-06-01 that the marketing application for Laikangqita monoclonal antibody injection was accepted for review by China's NMPA. Medium importance as a key drug development milestone.
Presentation of positive long-term follow-up data for IBI363 (PD-1/IL-2) at the 2026 ASCO annual meeting; 5-10% price impact estimated due to clinical data validation scheduled
Provided a business update on June 1, 2026, maintaining full-year 2026 revenue growth guidance of 13-17% and reporting 69 new projects; medium importance reflects an estimated price impact of 5% or more.
Announced a collaboration with Integrated DNA Technologies (IDT) to launch integrated workflows for oncology research, combining IDT's library prep with Illumina's DRAGEN analysis platform.
Announcement of strategic global licensing agreement with Pfizer for 12 cancer medicines ($10.5B total value); >10% price impact estimated due to massive deal size expected
The 12th Board of Directors was elected at the AGM on 2026-05-29, with Mr. Zhu Baoguo as Chairman and Mr. Liu Daping as President. Low importance as routine governance changes.
Announced that subsidiary Shanghai Henlius Biotech's Pertuzumab Injection (brand name 汉倍优®) was approved for marketing by China's NMPA. Low importance as subsidiary product approvals typically have a limited price impact (<5%).
Ex-dividend date on May 29, 2026, for a final dividend of CNY 1.57927 per share for the year 2025; low importance as the price adjustment is expected to be >=1%.